Inveresk (NASDAQ:IRGI)
Historical Stock Chart
From Oct 2019 to Oct 2024
Inveresk Research Group, Inc. Files Shelf Registration Statement With the
Securities and Exchange Commission
CARY, N.C., March 9 /PRNewswire-FirstCall/ -- Inveresk Research Group, Inc.
today announced the filing of a registration statement with theSecurities and
Exchange Commission covering the re-sale of an aggregate of up to 8,669,714
shares of common stock. All of the shares covered by the registration statement
are owned by the selling stockholders named in the filing. None of the shares
covered by the registration statement will be sold for the account of Inveresk
Research Group, Inc.
The registration statement on Form S-3 has been filed with the Securities and
Exchange Commission but has not yet become effective. These shares may notbe
sold nor may offers to buy be accepted prior to the time the registration
statement becomes effective. This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be any sale of
these shares in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any
such state.
Inveresk is the leading provider of drug development services to companies in
the pharmaceutical andbiotechnology industries. The company is based in Cary,
North Carolina with major facilities also in Edinburgh, Scotland and Montreal,
Canada.
DATASOURCE: Inveresk Research Group, Inc.
CONTACT: Matt Dallas for Inveresk Research Group, Inc., +1-212-850-5627